Korro Bio Q2 2025 net loss $25.8M; cash $119.6M; KRRO-110 interim data on track H2 2025

Korro Bio, Inc.

2025-Q2 EPS reported -$5.24 revenue$4,010,000

Cash, cash equivalents and marketable securities of $119.6M as of June 30, 2025, expected to fund operations into 2027.
Net loss $25.8M for Q2 2025 vs $21.8M in Q2 2024; R&D expenses $21.0M (up from $17.1M).
Collaboration revenue of $1.5M from Novo Nordisk partnership; zero collaboration revenue in prior year quarter.
Phase 1/2a REWRITE trial of KRRO-110 for AATD: over 80% of planned healthy volunteers dosed; interim SAD readout expected H2 2025.
KRRO-110 received EMA Orphan Drug Designation for AATD; rare metabolic disorder development candidate to be announced by end of 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.